From hypertension to hypertrophy to heart failure: The role of cardiotrophin-1

Journal of Hypertension

Volumn 31, Issue 3, 2013, Pages 474-476

  Schillaci, Giuseppe ^a,b   Pucci, Giacomo ^a,b   Perlini, Stefano ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b S MARIA HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTROPHIN 1; CYTOKINE;

CLINICAL PRACTICE; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTROPHY; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; FEMALE; HEART VENTRICLE; MALE; METABOLISM; PATHOPHYSIOLOGY; SYSTOLE;

CYTOKINES; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; SYSTOLE;

EID: 84884192022     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835ed4bb     Document Type: Note

References (31)

1. Krum H, Abraham WT. Heart failure. Lancet 2009; 373:941-955.
2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562. (Pubitemid 26154241)
3. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119:3070-3077.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005; 112:e154-e235.
5. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156:1789-1796.
6. de Simone G, Di Lorenzo L, Costantino G, Moccia D, Buonissimo S, de Divitiis O. Supernormal contractility in primary hypertension without left ventricular hypertrophy. Hypertension 1988; 11:457-463.
7. Lutas EM, Devereux RB, Reis G, Alderman MH, Pickering TG, Borer JS, Laragh JH. Increased cardiac performance in mild essential hypertension: left ventricular mechanics. Hypertension 1985; 7:979-988. (Pubitemid 16147481)
8. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26:195-202.
9. de Simone G, Devereux RB, Celentano A, Roman MJ. Left ventricular chamber and wall mechanics in the presence of concentric geometry. J Hypertens 1999; 17:1001-1006. (Pubitemid 29322189)
10. Schillaci G, Verdecchia P, Reboldi G, Pede S, Porcellati C. Subclinical left ventricular dysfunction in systemic hypertension and the role of 24-h blood pressure. Am J Cardiol 2000; 86:509-513.
11. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension 2005; 45:412-418. (Pubitemid 40326250)
12. Schillaci G, Vaudo G, Pasqualini L, Reboldi G, Porcellati C, Verdecchia P. Left ventricular mass and systolic dysfunction in essential hypertension. J Hum Hypertens 2002; 16:117-122. (Pubitemid 34182921)
13. Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C, et al. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am Heart J 2001; 141:784-791. (Pubitemid 32378488)
14. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics: an independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93:259-265. (Pubitemid 26031483)
15. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103:678-683. (Pubitemid 32144196)
16. Celentano A, Palmieri V, Arezzi E, Mureddu GF, Sabatella M, Di Minno G, De Simone G. Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. J Hypertens 2003; 21:1415-1423.
17. de Simone G, Pasanisi F, Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension 2001; 38:13-18. (Pubitemid 34224764)
18. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:2148-2159.
19. González A, López B, Martín-Raymondi D, Lozano E, Varo N, Barba J, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005; 23:2297-2304. (Pubitemid 41666760)
20. López-Andrés N, Fortuno MA, Díez J, Zannad F, Lacolley P, Rossignol P. Vascular effects of cardiotrophin-1: a role in hypertension? J Hypertens 2010; 28:1261-1272.
21. López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012; 60:563-573.
22. López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005; 23:625-632. (Pubitemid 40684722)
23. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001; 3:15-19. (Pubitemid 32127104)
24. López-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013; 61:120-129.
25. López B, Castellano JM, González A, Barba J, Díez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension 2007; 50:977-983. (Pubitemid 350287544)
26. López B, González A, Querejeta R, Barba J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens 2009; 27:418-424.
27. Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J 2011; 32:177-183.
28. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 38:1485-1490. (Pubitemid 33033030)
29. Zile MR, DeSantis SM, Baicu CF, Stroud RI, Thompson SB, McClure SD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4:246-256.
30. Ravassa S, Beloqui O, Varo N, Barba J, López B, Beaumont J, et al. Association of cardiotrophin-1 with left ventricular systolic properties in hypertensive patients. J Hypertens 2013; 31:587-594.
31. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115:949-952. (Pubitemid 46328287)